Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Thibaud Kössler; Maria Alsina; Dirk Arnold; Irit Ben-Aharon; Manfred B. Lutz; Radka Obermannova; Mark Peeters; Francesco Sclafani; Elizabeth Smyth; Juan Valle; Anna Dorothea Wagner; Lujan Wyrwicz; Elisa Fontana; Markus  Moehler

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Thibaud Kössler, Maria Alsina, Dirk Arnold, Irit Ben-Aharon, Manfred B. Lutz, Radka Obermannova, Mark Peeters, Francesco Sclafani, Elizabeth Smyth, Juan Valle, Anna Dorothea Wagner, Lujan Wyrwicz, Elisa Fontana, Markus Moehler

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. Last month, at the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice.
Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.

Original language	English
Journal	British Journal of Cancer
Publication status	Accepted/In press - 17 Jun 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Embargoed Document

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group_ Clean Version
Accepted author manuscript, 58.2 KB
Embargo ends: 1/01/31

Cite this

@article{bcf024d1b2ea423ab053b4b83b80c43a,

title = "Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group",

abstract = "Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. Last month, at the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice. ",

author = "Thibaud K{\"o}ssler and Maria Alsina and Dirk Arnold and Irit Ben-Aharon and Lutz, {Manfred B.} and Radka Obermannova and Mark Peeters and Francesco Sclafani and Elizabeth Smyth and Juan Valle and Wagner, {Anna Dorothea} and Lujan Wyrwicz and Elisa Fontana and Markus Moehler",

year = "2021",

month = jun,

day = "17",

language = "English",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

}

TY - JOUR

T1 - Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

AU - Kössler, Thibaud

AU - Alsina, Maria

AU - Arnold, Dirk

AU - Ben-Aharon, Irit

AU - Lutz, Manfred B.

AU - Obermannova, Radka

AU - Peeters, Mark

AU - Sclafani, Francesco

AU - Smyth, Elizabeth

AU - Valle, Juan

AU - Wagner, Anna Dorothea

AU - Wyrwicz, Lujan

AU - Fontana, Elisa

AU - Moehler , Markus

PY - 2021/6/17

Y1 - 2021/6/17

N2 - Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. Last month, at the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.

AB - Last year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. Last month, at the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.

M3 - Article

SN - 0007-0920

JO - British Journal of Cancer

JF - British Journal of Cancer

ER -

Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

Abstract

UN SDGs

Embargoed Document

Fingerprint

Cite this